Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.62 |
| ▸ | TSHR | P16473 | 10/20 | 0.62 |
| ▸ | USP2 | O75604 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050997 | 1.00 | CYP2D6 (0.62) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL30049623 | 0.91 | CYP3A4 (0.56) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL27162473 | 0.91 | CYP3A4 (0.56) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL27161433 | 0.90 | CYP2D6 (0.48) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL30050935 | 0.90 | CYP2D6 (0.48) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL30049383 | 0.90 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL27162693 | 0.90 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL27162042 | 0.88 | CYP3A4 (0.47) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL30049081 | 0.88 | CYP3A4 (0.47) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 | |
| SCHEMBL30050972 | 0.85 | CYP3A4 (0.42) | CYP2D6CYP3A4TSHRUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | claimed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | claimed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | CYP2D6 514/4885CYP3A4 497/4885TSHR 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.